Skip to main content

Table 1 Demographic characteristics of the study participants at baseline

From: Effect of a multi-dimensional case management model on anti-retroviral therapy-related outcomes among people living with human immunodeficiency virus in Beijing, China

Variable Total (n = 4906) Control group (n = 1549) Intervention group (n = 3357) P-value
Age (Median, IQR) 35 (30–43) 37 (32–46) 33 (29–40) < 0.001
< 30 1181 (24.1) 165 (10.7) 1016 (30.3)  
30–49 3100 (63.2) 1136 (73.3) 1964 (58.5)  
50+ 625 (12.7) 248 (16.0) 377 (11.2)  
Gender     < 0.001
 Male 4716 (96.1) 1467 (94.7) 3249 (96.8)  
 Female 190 (8.3) 82 (5.3) 108 (3.2)  
Marital status     < 0.001
 Married 3400 (69.3) 937 (60.5) 2463 (73.4)  
 Cohabitating 1279 (26.1) 525 (33.9) 754 (22.5)  
 Single 203 (4.1) 77 (5.0) 126 (3.8)  
 Separated/divorced 24 (0.5) 10 (0.6) 14 (0.4)  
Route of transmission     < 0.001
 Blood transfusion 75 (1.5) 23 (1.5) 52 (1.5)  
 Homosexual 4289 (87.4) 1282 (82.8) 3007 (89.6)  
 Heterosexual 329 (6.7) 152 (9.8) 177 (5.3)  
 Mother to child/other 213 (4.3) 92 (5.9) 121 (3.6)  
WHO Clinical stage2     < 0.001
 Stage I and Stage II 4368 (89.0) 1292 (83.4) 3076 (91.6)  
 Stage III and Stage IV 538 (11.0) 192 (16.6) 281 (8.4)  
CD4 cell counts
(Median, IQR)
300 (191–416) 264 (163–351) 322 (207–442) < 0.001
  < 500 4229 (86.2) 1432 (92.5) 2797 (83.3)  
 500+ 677 (13.8) 117 (7.5) 560 (16.7)  
Viral loads3(Mean ± SD) 4.2 ± 0.83 4.2 ± 0.73 4.2 ± 0.86 0.030
ART Regimen     0.530
 EFV/LPV/r + 3TC + AZT/TDF 4777 (97.4) 1505 (97.2) 3066 (97.5)  
 Other 129 (2.6) 44 (2.8) 85 (2.5)  
  1. IQR interquartile range; WHO World Health Organization, ART anti-retroviral therapy; EFV Efavirenz; 3TC Lamivudine; AZT Zidovudine; TDF Tenofovir; LPV/r Kaletra
  2. 2 WHO Clinical Stage: a way to categorize HIV disease severity based on new or recurrent clinical events. There are 4 WHO clinical stages which range from mild symptoms (WHO clinical stage 1) to severe symptoms (WHO clinical stage 4)
  3. 3915 did not have baseline viral loads